A major new class of antibodies can make the four different types of dengue virus non-infectious, new research shows.
The discovery could lead to the development of better vaccines and laboratory tests that eventually could lead to reductions in the incidence of dengue.
Published in Nature Immunology, the research outlines the first reported incidence of an antibody that can neutralize all four type of the dengue virus (DENV) when it is produced from human or mosquito cells.
The findings could pave the way for the development of vaccines that target all four strains of the dengue virus,which are currently not available.
“There is an urgent need to reduce incidence of people suffering dengue, and understand the human immune response to infection and the response following vaccination,” says Cameron Simmons, professor with the Doherty Institute for Infection and Immunity at University of Melbourne.
“This unique discovery makes the future development of vaccines that could prevent the spread of the disease a realistic goal and may also pave the way for a universal DENV vaccine.”
For the study, researchers analyzed a large group of anti-dengue antibodies from human patients who were infected with the virus.
They found a new class of antibodies that are highly effective at neutralizing the virus, which bind to a newly discovered epitope—a unique structure that antibodies can recognize and bind to—that is present in all forms of the disease.
The geographical spread of the disease continues to widen, threatening the Southern United States and Australia. There is also concern of possible spread to Southern Europe.
Infection with one form of the virus leads to life-long protection against that specific form but not against others. In addition, antibody recognition of virus particles is complicated by dramatic changes in the shell of the virus during its life cycle.
Researchers at Imperial College London led the study.